| Lantus |
All Financial Data in US $ (mln) |
| Word Search (Top 10 - by date) |
EPS Growth in Q2 2010
Sanofi-Aventis
(July 29, 2010)
|
Amylin Pharmaceuticals Reports Second Quarter Financial Results
Amylin Pharmaceuticals
(July 21, 2010)
|
Biodel Reports Progress with Development of Glucose-Regulated 'Smart' Basal Insulin
Biodel
(July 12, 2010)
|
Less Glycemic Variability, Better Patient Reported Outcomes with Lantus® and Apidra® Regimen vs. Premix Analog Insulin
Sanofi-Aventis
(June 26, 2010)
|
Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
Eli Lilly
(June 26, 2010)
|
Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
Amylin Pharmaceuticals
(June 26, 2010)
|
BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010
Eli Lilly
(June 26, 2010)
|
BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010
Amylin Pharmaceuticals
(June 26, 2010)
|
BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010
Alkermes
(June 26, 2010)
|
Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R)
Eli Lilly
(June 26, 2010)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
| Summary Product Name Information |
|
|
| Product Sales Summary 2007/08 |
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2007 |
2008
|
2008 |
| Lantus2 |
|
|
|
2,785 |
3,600 |
|
+29% |
|
|
Note: Shaded Cells3 |
|
|
More Product Information for EvaluatePharma® subscribersSubscribers see:
- Sales (historic and forecast to 2016 where available) listed by the reporting company or companies, including royalty, license and JV revenue where applicable
- Details of all events impacting the product
- Detailed product information, including sales forecasts listed by the reporting company or companies, indications (approved and in trial)
|
Register to access more FREE content:
- 2009 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
|
|
|
|